REVIVE Blend (GHK-Cu / CJC-1295 / Ipamorelin / TB-500): What It Is, Where to Get It Prescribed, and What It Costs

REVIVE is not a single molecule. It is four independently studied peptides — GHK-Cu, CJC-1295, ipamorelin and TB-500 — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Two are repair peptides and two are growth hormone secretagogues, which makes it a different kind of blend from an all-repair formula like KLOW. Each has its own literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal. That shapes everything on this page: "does REVIVE work" has to be broken into four questions, because the combination itself has never been studied as a combination.

The rationale prescribers give is that recovery has two halves. One is local: damaged tissue needs cells to migrate in, blood vessels to grow, and collagen to be laid down and remodelled, which is what GHK-Cu and TB-500 are described as acting on. The other is systemic: the body does most of its repair overnight, during the growth hormone pulse that accompanies early deep sleep, a pulse described as flattening with age and heavy training load. CJC-1295 and ipamorelin are two different signals that converge on the pituitary to produce a larger pulse. Dosing at bedtime is meant to put the repair peptides and the pulse in the same window.

The proportions are worth noticing. GHK-Cu is 50 of the 70 mg in the vial, so by mass REVIVE is mostly a GHK-Cu preparation. The two secretagogues are in the same two-to-one ipamorelin-to-CJC-1295 ratio as the standalone CJC-1295 / Ipamorelin product. TB-500 is the smallest component at 2 mg per vial, 0.1 mg per dose — much less than a standalone TB-500 prescription delivers. The ratio is fixed by the formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not growth hormone. CJC-1295 and ipamorelin prompt the pituitary to release its own growth hormone in pulses; nothing in the vial is the hormone itself, and nothing in it is a steroid. It is not a painkiller and has no described analgesic mechanism. It is not a treatment for a structural problem — a full-thickness tendon rupture, a displaced fracture or a locking joint is a surgical or imaging question, and no peptide changes that. And it is not a shortcut around rehabilitation or sleep: every component is described as supporting a process the body is already running, not as creating one.

GHK-Cu is a tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It occurs naturally in human plasma, where its concentration is reported to decline with age. The copper-carrying role is the basis for most of its described effects, because collagen cross-linking, elastin formation and several antioxidant enzymes are copper-dependent.

In cell and animal work, and in reviews in Biomed Research International (2015) and the International Journal of Molecular Sciences (2018), GHK-Cu is described as increasing synthesis of collagen, elastin and glycosaminoglycans, shifting the balance between matrix metalloproteinases and their inhibitors, supporting angiogenesis, and having antioxidant and anti-inflammatory activity. Gene-expression work reports effects across a large number of genes rather than one pathway. A fuller treatment is on the GHK-Cu page.

CJC-1295 is a modified fragment of growth-hormone-releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone. It binds the GHRH receptor on pituitary somatotroph cells and drives both release of stored hormone and synthesis of more. Four amino-acid substitutions protect it from the enzyme that breaks down native GHRH and sermorelin, which is why it is described as longer-acting than sermorelin.

One point of precision the name hides: CJC-1295 exists in two forms. The version in the published human trials carried a "drug affinity complex" (DAC), an albumin-binding tag that keeps it circulating for about a week. The version in compounded blends is CJC-1295 without DAC, also called modified GRF (1-29), which lasts roughly half an hour. What carries over from the DAC trials is how the pituitary responds to GHRH stimulation, not the duration; the short-acting form is why it is dosed daily and paired with ipamorelin for one clean pulse.

Ipamorelin is a five-amino-acid peptide developed in the 1990s and described in the European Journal of Endocrinology in 1998 as "the first selective growth hormone secretagogue." It acts at the growth hormone secretagogue receptor, the receptor ghrelin uses, rather than the GHRH receptor. That is the reason it is paired with CJC-1295: two different receptors on the same pituitary cells, converging on one pulse.

The 1998 work is the basis for the word "selective." In pigs, the older secretagogues GHRP-6 and GHRP-2 released growth hormone but also raised ACTH and cortisol, whereas ipamorelin released growth hormone at comparable potency without raising either. A 1999 study in Pharmaceutical Research modelled the response to intravenous ipamorelin in healthy male volunteers and reported a single episode of growth hormone release peaking at about forty minutes and returning to baseline. A fuller treatment is on the ipamorelin page.

TB-500 is a synthetic peptide reproducing the actin-binding segment of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant inside many human cells. A 2005 review in Trends in Molecular Medicine describes thymosin beta-4's primary function as binding actin monomers — the protein that gives a cell its shape and lets it move — and the consequence described in the research is cell migration: repair cells moving into a wound. A 1999 paper in the Journal of Investigative Dermatology reported faster wound closure and increased cell migration with thymosin beta-4 in rats and in cultured human cells, and a 2012 review in Expert Opinion on Biological Therapy covers described effects on angiogenesis, inflammatory mediators and laminin-5. One point of precision: most of that literature concerns the full-length protein. TB-500, the fragment, is assumed to share the actin-binding mechanism; the direct evidence for the fragment itself is much thinner. A fuller treatment is on the TB-500 page.

The map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the four act together when injected together.

This is where the human evidence for REVIVE lives, and it belongs to the secretagogue half. A 2006 study in the Journal of Clinical Endocrinology and Metabolism gave healthy adults single and repeated doses of CJC-1295 with DAC and reported dose-dependent rises in growth hormone lasting days and in IGF-1 lasting more than a week, described as well tolerated. A second 2006 paper in the same journal sampled blood every ten minutes and reported that the pituitary's pulsatile pattern was preserved during stimulation — more hormone per pulse rather than a flat elevation. For ipamorelin, the 1999 volunteer study confirmed that it releases growth hormone in people.

What these studies establish is narrow: the two secretagogues raise growth hormone and IGF-1 in humans, and the pituitary stays in control of the pattern. They did not measure sleep, recovery, tissue repair or body composition.

This rests on TB-500, and on GHK-Cu's matrix work. Animal and cell studies of thymosin beta-4 report faster wound closure, cell migration into injured tissue and effects on new vessel growth, reviewed in the 2005 and 2012 papers above. For the TB-500 fragment specifically, the tendon and muscle case is inferred from the full-length protein's work rather than shown directly, and no study has looked at the 0.1 mg per dose that REVIVE delivers.

GHK-Cu has the deepest literature of the four and is the only component with human tissue studies of any size. The human work is mostly small studies of topical GHK-Cu on facial skin — reporting changes in firmness, fine lines and elasticity — and wound-healing reports, summarised in the 2015 and 2018 reviews. None of the human studies used the injectable form.

These are the uses the secretagogue half is actually prescribed for, and there are no trials of CJC-1295 or ipamorelin, alone or together, measuring any of them. The case is inferred from physiology — growth hormone is released mainly during deep sleep and acts on muscle, bone, connective tissue and fat through IGF-1 — and from prescribing experience. That inference is reasonable and is why physicians prescribe secretagogues; it is not the same as a measured outcome.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of REVIVE, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• CJC-1295 has 2006 healthy-adult trials of the DAC form showing dose-dependent rises in growth hormone and IGF-1. There are no trials of the daily-dosed no-DAC form for any wellness use.
• Ipamorelin has a 1999 pharmacokinetic study in healthy male volunteers confirming growth hormone release, and a 2014 randomised, placebo-controlled phase 2 trial in bowel-resection patients for postoperative ileus, which did not meet its endpoints. There are no human data for the subcutaneous route and no trials for sleep, recovery or body composition.
• GHK-Cu has small human studies, mostly of topical application to skin. There are no randomised controlled trials of injectable GHK-Cu.
• TB-500 has no randomised human trials. The full-length thymosin beta-4 protein has been studied in early-phase human trials for chronic dermal wounds and corneal conditions, but those used the whole protein, not the fragment.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe REVIVE on. But the accurate framing is "two components shown to raise growth hormone in humans, two described in preclinical research, all four used clinically," not "proven in people."

• That four peptides together do more than any one alone. No study has compared the blend with its components.
• That a larger overnight growth hormone pulse produces a measurable recovery or body-composition change in the people typically prescribed it. That trial has not been run.
• An effect size for any indication, or a timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is part of why bloodwork is commonly required and a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. Neither REVIVE nor any component is approved for anything.

Between 2023 and 2026 all four components appeared on the FDA's interim 503A bulk drug substances list, most in Category 2 — the category for nominated substances flagged as presenting significant safety risks. What has happened since differs by component.

Both secretagogues have been through the FDA's Pharmacy Compounding Advisory Committee in full, and both were voted against. On 29 October 2024 the committee considered ipamorelin (free base) and ipamorelin acetate, evaluated for growth hormone deficiency and postoperative ileus, and voted 0 in favour, 12 against, with 1 abstention, on adding them to the 503A Bulks List, citing a lack of safety and efficacy data for those two uses. On 4 December 2024 the committee considered the CJC-1295 family, evaluated for growth hormone deficiency, and voted 0–13 against CJC-1295 (free base), 1–12 against CJC-1295 acetate, and 0–13 against each of the three DAC forms.

Two things about those votes are worth understanding. The committee evaluates a substance for the uses in its nomination package — here growth hormone deficiency and postoperative ileus, for which FDA-approved drugs already exist — not for the uses it is actually prescribed for. And a committee vote is a recommendation, not a rule; the FDA issues its own determination afterwards, and as of September 2026 none has been issued for either. On the FDA's safety-risks page, current as of 22 April 2026, both CJC-1295 and ipamorelin acetate appear in the table of substances "nominated but withdrawn" rather than in 503A Category 2; ipamorelin acetate retains a Category 2 entry only on the separate 503B list for outsourcing facilities, which is not the pathway a patient-specific prescription compounded by a 503A pharmacy uses. Neither was on the committee's July 2026 agenda.

On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective about a week later, and TB-500 was one of them. On 23 July 2026 the Pharmacy Compounding Advisory Committee reviewed TB-500 for wound healing and voted 8–6, with one abstention, to recommend adding it — as the free base and the acetate — to the 503A Bulks List. FDA's own scientists had recommended against inclusion, citing insufficient safety, efficacy and characterisation data; the committee weighed the presentations and voted the other way. The FDA's final determination is pending.

Injectable GHK-Cu was among the same twelve April 2026 removals, and the non-injectable form was removed from Category 1 at the same time because its nomination was withdrawn. GHK-Cu was not on the July agenda; the FDA has said the committee will consider it, along with four other April removals, at a meeting to be held before the end of February 2027. Until then it is where TB-500 was between April and July: no longer flagged, not yet reviewed for the positive list.

None of the four components is currently in 503A Category 2. TB-500 has been formally recommended for the positive list and awaits final FDA action; GHK-Cu is scheduled for review; CJC-1295 and ipamorelin were recommended against by the committee for the specific clinical uses it examined, with no final FDA rule issued for either. All four remain prescription-only substances that licensed pharmacies compound to a physician's prescription. None is an FDA-approved drug product, and compounded medications never are.

The secretagogue half is the part most people notice first, if they notice anything. Prescribers describe deeper or more consolidated sleep within the first week or two of bedtime dosing; some people report a brief flush or tingling after injecting. Injection-site tenderness is the most commonly reported observation. Noticing nothing in this window is normal and is not a sign the course is not working.

This is the window one vial covers. Prescribers most often describe morning recovery from training feeling easier and a reduced background ache in a problem area. IGF-1 measured at this point is how a physician tells whether the pituitary is responding and the dose is right; that is the objective marker, and it is why bloodwork is commonly required.

Where tissue-level change happens, this is where it would be expected to show, based on the animal timelines for the soft-tissue work. Prescribers describe it as improved tolerance to loading — the point at which rehabilitation progress usually becomes visible. It typically takes a second vial to reach.

Skin turnover is slow, and GHK-Cu's described effects on collagen and matrix are slow by nature; where texture or tone changes are described, they are a two-month-plus proposition. After a course the growth hormone pulse returns to its baseline pattern — no suppression of the axis is described for secretagogues, because the pituitary was doing the releasing throughout — and no rebound is described for any component. Whether any benefit persists depends on whether the underlying tissue actually changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split: 2.5 mg GHK-Cu, 0.3 mg CJC-1295, 0.6 mg ipamorelin and 0.1 mg TB-500; you cannot take more of one and less of another. If your directions and syringe markings appear to disagree, ask before dosing.

Bedtime is not arbitrary. The largest natural growth hormone pulse of the day occurs in the first hours of sleep, and the secretagogues are timed to add to it. Prescribers also direct that the dose be taken on an empty stomach where possible, because the insulin rise after a meal blunts growth hormone release. Weekends off is part of the schedule, not a missed dose: prescribers describe intermittent dosing as keeping the pituitary responsive.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. The mechanisms described are systemic, so there is no reason to inject near an injury. Your directions will say.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a monthly cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating is on the label; a multi-peptide vial is not something to keep past it.

The difference is the middle two components. KLOW and GLOW keep GHK-Cu and TB-500 and pair them with BPC-157 — KLOW adds KPV as well — so they are all-repair formulas with no growth hormone component. REVIVE drops BPC-157 and adds CJC-1295 and ipamorelin. If a gut complaint or a specific tendon is the picture, BPC-157 is the component with that literature and a repair blend fits better; if sleep and overnight recovery are the picture, REVIVE is the one with a secretagogue.

CJC-1295 / Ipamorelin is the secretagogue half on its own, in the same two-to-one ratio. REVIVE adds 2.5 mg GHK-Cu and 0.1 mg TB-500 to each dose. For someone whose goal is the growth hormone pulse alone, the two-peptide product is the more targeted prescription and a physician may reasonably prefer it. The bloodwork picture is the same for both, because it is driven by the secretagogues.

The ETERNAL blend shares GHK-Cu and TB-500 with REVIVE and swaps the secretagogues for BPC-157 and epithalon. It is the closer comparison for someone who wants that pairing without a growth hormone component or the glucose considerations. Which fits is a physician's call, made on what you are actually treating.